BACKGROUND AND PURPOSE: Olesoxime is a small cholesterol-oxime promoting rat embryonic motor neurons survival in the absence of trophic factors. Because olesoxime can substitute for neurotrophic factors in many situations, and to gain further understanding of its mechanism of action, we wondered if it could prevent neuronal death induced by camptothecin (CPT) and compared its effects with those of brain-derived neurotrophic factor (BDNF). EXPERIMENTAL APPROACH: E17 rat embryonic cortical neurons were treated with olesoxime, BDNF or vehicle and intoxicated with CPT. Caspase-dependent and caspase-independent death pathways along with pro-survival pathways activation were explored. KEY RESULTS: As previously reported for BDNF, olesoxime dose-dependently delayed CPT-induced cell death. Both compounds acted downstream of p53 activation preventing cytochrome c release and caspases activation. When caspase activation was blocked, both olesoxime and BDNF provided additional neuroprotective effect, potentially through the prevention of apoptosis-inducing factor release from mitochondria. While BDNF activates both the PI3K/Akt and the ERK pathway, olesoxime induced only a late activation of the ERK pathways, which did not seem to play a major role in its neuroprotection against CPT. Rather, our results favour preserved mitochondrial membrane integrity by olesoxime. CONCLUSIONS AND IMPLICATIONS: Albeit different, olesoxime and BDNF mechanisms for neuroprotection converge to preserve mitochondrial function. These findings emphasize the importance of targeting the mitochondria in the process of neurodegeneration. Importantly olesoxime, by mimicking neurotrophin pro-survival activities without impacting PI3K/Akt and ERK signalling, may have greater therapeutic potential in many diseases where neurotrophins were considered as a therapeutic solution.
BACKGROUND AND PURPOSE:Olesoxime is a small cholesterol-oxime promoting rat embryonic motor neurons survival in the absence of trophic factors. Because olesoxime can substitute for neurotrophic factors in many situations, and to gain further understanding of its mechanism of action, we wondered if it could prevent neuronal death induced by camptothecin (CPT) and compared its effects with those of brain-derived neurotrophic factor (BDNF). EXPERIMENTAL APPROACH: E17 ratembryonic cortical neurons were treated with olesoxime, BDNF or vehicle and intoxicated with CPT. Caspase-dependent and caspase-independent death pathways along with pro-survival pathways activation were explored. KEY RESULTS: As previously reported for BDNF, olesoxime dose-dependently delayed CPT-induced cell death. Both compounds acted downstream of p53 activation preventing cytochrome c release and caspases activation. When caspase activation was blocked, both olesoxime and BDNF provided additional neuroprotective effect, potentially through the prevention of apoptosis-inducing factor release from mitochondria. While BDNF activates both the PI3K/Akt and the ERK pathway, olesoxime induced only a late activation of the ERK pathways, which did not seem to play a major role in its neuroprotection against CPT. Rather, our results favour preserved mitochondrial membrane integrity by olesoxime. CONCLUSIONS AND IMPLICATIONS: Albeit different, olesoxime and BDNF mechanisms for neuroprotection converge to preserve mitochondrial function. These findings emphasize the importance of targeting the mitochondria in the process of neurodegeneration. Importantly olesoxime, by mimicking neurotrophin pro-survival activities without impacting PI3K/Akt and ERK signalling, may have greater therapeutic potential in many diseases where neurotrophins were considered as a therapeutic solution.
Authors: R D Almeida; B J Manadas; C V Melo; J R Gomes; C S Mendes; M M Grãos; R F Carvalho; A P Carvalho; C B Duarte Journal: Cell Death Differ Date: 2005-10 Impact factor: 15.828
Authors: Yi Zhang; Dianbo Qu; Erick J Morris; Michael J O'Hare; Steven M Callaghan; Ruth S Slack; Herbert M Geller; David S Park Journal: J Neurosci Date: 2006-08-23 Impact factor: 6.167
Authors: Eric C C Cheung; Lysanne Melanson-Drapeau; Sean P Cregan; Jacqueline L Vanderluit; Kerry L Ferguson; William C McIntosh; David S Park; Steffany A L Bennett; Ruth S Slack Journal: J Neurosci Date: 2005-02-09 Impact factor: 6.167
Authors: Daming Zhu; Xuan Wu; Kenneth I Strauss; Robert H Lipsky; Zehra Qureshi; Artin Terhakopian; Antonello Novelli; Krishna Banaudha; Ann M Marini Journal: J Neurosci Res Date: 2005-04-01 Impact factor: 4.164
Authors: Anthony E Lang; Steven Gill; Nik K Patel; Andres Lozano; John G Nutt; Richard Penn; David J Brooks; Gary Hotton; Elena Moro; Peter Heywood; Matthew A Brodsky; Kim Burchiel; Patrick Kelly; Arif Dalvi; Burton Scott; Mark Stacy; Dennis Turner; V G Frederich Wooten; William J Elias; Edward R Laws; Vijay Dhawan; A Jon Stoessl; James Matcham; Robert J Coffey; Michael Traub Journal: Ann Neurol Date: 2006-03 Impact factor: 10.422
Authors: Franziska Richter; Fuying Gao; Vera Medvedeva; Patrick Lee; Nicholas Bove; Sheila M Fleming; Magali Michaud; Vincent Lemesre; Stefano Patassini; Krystal De La Rosa; Caitlin K Mulligan; Pedrom C Sioshansi; Chunni Zhu; Giovanni Coppola; Thierry Bordet; Rebecca M Pruss; Marie-Françoise Chesselet Journal: Neurobiol Dis Date: 2014-05-18 Impact factor: 5.996
Authors: C Gouarné; J Tracz; M Giraudon Paoli; V Deluca; M Seimandi; G Tardif; M Xilouri; L Stefanis; T Bordet; R M Pruss Journal: Br J Pharmacol Date: 2014-12-01 Impact factor: 8.739
Authors: Johannes Beiersdorf; Zsofia Hevesi; Daniela Calvigioni; Jakob Pyszkowski; Roman Romanov; Edit Szodorai; Gert Lubec; Sally Shirran; Catherine H Botting; Siegfried Kasper; Geoffrey W Guy; Roy Gray; Vincenzo Di Marzo; Tibor Harkany; Erik Keimpema Journal: JCI Insight Date: 2020-12-03